These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1596 related articles for article (PubMed ID: 18728030)

  • 21. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
    De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
    Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
    Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
    Bone Marrow Transplant; 2004 Oct; 34(8):721-7. PubMed ID: 15322568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.
    Garderet L; Labopin M; Gorin NC; Polge E; Fouillard L; Ehninger GE; Ringden O; Finke J; Tura S; Frassoni F
    Bone Marrow Transplant; 2003 Jan; 31(1):23-9. PubMed ID: 12621503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.
    Martino R; Giralt S; Caballero MD; Mackinnon S; Corradini P; Fernández-Avilés F; San Miguel J; Sierra J
    Haematologica; 2003 May; 88(5):555-60. PubMed ID: 12745275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
    Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
    Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
    Merup M; Lazarevic V; Nahi H; Andreasson B; Malm C; Nilsson L; Brune M; LeBlanc K; Kutti J; Birgegård G;
    Br J Haematol; 2006 Nov; 135(3):367-73. PubMed ID: 16972981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.
    Lemoli RM; D'Addio A; Marotta G; Pezzullo L; Zuffa E; Montanari M; De Vivo A; Bonini A; Galieni P; Carella AM; Guidi S; Michieli M; Olivieri A; Bosi A
    Bone Marrow Transplant; 2010 Apr; 45(4):640-6. PubMed ID: 19802019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
    Nivison-Smith I; Dodds AJ; Butler J; Bradstock KF; Ma DD; Simpson JM; Szer J
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry.
    Crocchiolo R; Ciceri F; Fleischhauer K; Oneto R; Bruno B; Pollichieni S; Sacchi N; Sormani MP; Fanin R; Bandini G; Bonifazi F; Bosi A; Rambaldi A; Alessandrino PE; Falda M; Bacigalupo A
    Bone Marrow Transplant; 2009 Nov; 44(9):571-7. PubMed ID: 19363528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.